Compare Asana Inc. (ASAN) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Biogen Inc — how do they compare? Asana Inc. trades at $7.37 (market cap $1.69B), while Biogen Inc trades at $201 (market cap $29.40B). The key difference: Biogen Inc is far larger — about 17.4× Asana Inc.'s market cap, and Biogen Inc is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | BIIB | |
|---|---|---|
Market Cap | $1.69B | $29.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.35 | $216.63 |
52-Week Low | $5.46 | $122.68 |
Enterprise Value | $1.51B | $31.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $7.33, down 0.54% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $378M in 2022 to $724M in 2025, though net losses persist. Recent Q1 2027 earnings beat expectations at $0.10 per share, and strategic acquisitions like StackAI enhance AI capabilities. Analyst consensus is mixed with 42% buy ratings and a $9.86 price target, representing 35% upside from current levels.
The outlook balances growth potential against profitability challenges. Positive catalysts include FedRAMP authorization for government contracts and AI innovation, but risks stem from intense competition with Microsoft and decelerating revenue growth. Cash flow turned positive in 2025, yet negative margins and high valuation multiples require careful monitoring for sustained improvement.
Biogen (BIIB) trades at $199.15, up 0.12% on the day, with a bullish technical signal from moving averages and RSI near oversold levels at 20.73. The company reported Q1 2026 EPS of $3.57, beating estimates of $3.05, continuing a trend of earnings surprises. Revenue for 2025 was $9.89B with a net income margin of 13.81%, while recent acquisitions like RayThera for up to $1B aim to bolster its immunology pipeline. Analyst consensus price target is $226.00, implying potential upside from current levels.
BIIB presents a mixed outlook with strong earnings momentum and strategic acquisitions offset by legacy drug sales declines and legal investigations. The stock's valuation at a P/E of 21.41 is reasonable relative to growth prospects, but investors face risks from pipeline execution and competitive pressures in biotech. Near-term catalysts include Alzheimer's data presentations at AAIC 2026 in July.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
